Prognostic impact of iliofemoral access-site calcification volume on outcomes after transcatheter aortic valve implantation - Summary - MDSpire

Prognostic impact of iliofemoral access-site calcification volume on outcomes after transcatheter aortic valve implantation

  • By

  • Vivian Vij

  • Katja Schauwienold

  • Jasmin Shamekhi

  • Samuel Muli

  • Mustafa Basha

  • Eleftherios Markidis

  • Andreas Zietzer

  • Philip Düsing

  • Muntadher Al Zaidi

  • Marcel Weber

  • Lara Al-Kassou

  • Tobias Zeus

  • Victor Mauri

  • Matti Adam

  • Jörg Schröder

  • Stephan Baldus

  • Malte Kelm

  • Nikolaus Marx

  • Farhad Bakhtiary

  • Enzo Lüsebrink

  • Sebastian Zimmer

  • Georg Nickenig

  • Alexander Sedaghat

  • Baravan Al-Kassou

  • June 11, 2026

  • 0 min

Share

Objective:

To investigate the prognostic significance of CT-assessed iliofemoral calcification burden in patients undergoing TAVI and evaluate the association between IASC-volume and mortality outcomes.

Approach:
    Key Findings:
    • Quantitative assessment of iliofemoral calcification volume is associated with peri-procedural complications and long-term mortality.
    Interpretation:

    Limitations:
    • The study was conducted at a single center, which may limit generalizability.
    • Follow-up data collection relied on outpatient visits and telephone interviews, which may introduce bias.
    Conclusion:

    IASC-volume is associated with mortality outcomes in TAVI patients.

Original Source(s)

Prognostic impact of iliofemoral access-site calcification volume on outcomes after transcatheter aortic valve implantation

  • by Vivian Vij, Katja Schauwienold, Jasmin Shamekhi, Samuel Muli, Mustafa Basha, Eleftherios Markidis, Andreas Zietzer, Philip Düsing, Muntadher Al Zaidi, Marcel Weber, Lara Al-Kassou, Tobias Zeus, Victor Mauri, Matti Adam, Jörg Schröder, Stephan Baldus, Malte Kelm, Nikolaus Marx, Farhad Bakhtiary, Enzo Lüsebrink, Sebastian Zimmer, Georg Nickenig, Alexander Sedaghat, Baravan Al-Kassou

  • June 11, 2026

Related Content

Revisiting the Ross operation: early results from a new Ross program at a cardiovascular center in South America

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Multidisciplinary management of Grade III circumferential mixed hemorrhoids in a patient with Marfan syndrome receiving long-term anticoagulation: a case report